1. Home
  2. AKRO vs RAMP Comparison

AKRO vs RAMP Comparison

Compare AKRO & RAMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • RAMP
  • Stock Information
  • Founded
  • AKRO 2017
  • RAMP 2018
  • Country
  • AKRO United States
  • RAMP United States
  • Employees
  • AKRO N/A
  • RAMP N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • RAMP EDP Services
  • Sector
  • AKRO Health Care
  • RAMP Technology
  • Exchange
  • AKRO Nasdaq
  • RAMP Nasdaq
  • Market Cap
  • AKRO 2.0B
  • RAMP 2.0B
  • IPO Year
  • AKRO 2019
  • RAMP 1987
  • Fundamental
  • Price
  • AKRO $25.14
  • RAMP $32.19
  • Analyst Decision
  • AKRO Strong Buy
  • RAMP Buy
  • Analyst Count
  • AKRO 8
  • RAMP 7
  • Target Price
  • AKRO $46.83
  • RAMP $39.71
  • AVG Volume (30 Days)
  • AKRO 842.7K
  • RAMP 499.0K
  • Earning Date
  • AKRO 02-27-2025
  • RAMP 02-06-2025
  • Dividend Yield
  • AKRO N/A
  • RAMP N/A
  • EPS Growth
  • AKRO N/A
  • RAMP N/A
  • EPS
  • AKRO N/A
  • RAMP 0.04
  • Revenue
  • AKRO N/A
  • RAMP $707,165,000.00
  • Revenue This Year
  • AKRO N/A
  • RAMP $13.82
  • Revenue Next Year
  • AKRO N/A
  • RAMP $9.09
  • P/E Ratio
  • AKRO N/A
  • RAMP $738.15
  • Revenue Growth
  • AKRO N/A
  • RAMP 13.84
  • 52 Week Low
  • AKRO $15.32
  • RAMP $21.45
  • 52 Week High
  • AKRO $37.00
  • RAMP $42.10
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 41.89
  • RAMP 63.92
  • Support Level
  • AKRO $21.34
  • RAMP $27.99
  • Resistance Level
  • AKRO $28.94
  • RAMP $31.90
  • Average True Range (ATR)
  • AKRO 1.38
  • RAMP 0.80
  • MACD
  • AKRO -0.27
  • RAMP 0.11
  • Stochastic Oscillator
  • AKRO 49.67
  • RAMP 89.94

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About RAMP LiveRamp Holdings Inc.

LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.

Share on Social Networks: